Molecular Targeted Therapies for Patients with Refractory Thyroid Cancer

被引：23

作者：

Chougnet, C.

Brassard, M.

Leboulleux, S.

Baudin, E.

Schlumberger, M. ^{[1
]}

机构：

[1] Inst Gustave Roussy, Ctr Reference Tumeurs Refractaires Thyroide, Dept Nucl Med & Endocrine Oncol, F-94800 Villejuif, France

来源：

CLINICAL ONCOLOGY | 2010年 / 22卷 / 06期

关键词：

Refractory thyroid cancer; targeted therapy; PHASE-II TRIAL; DOXORUBICIN PLUS CISPLATIN; ENDOTHELIAL GROWTH-FACTOR; ANTIGEN DOUBLING-TIMES; RADIOIODINE THERAPY; SOLID TUMORS; CARCINOMA; EXPRESSION; CALCITONIN; SORAFENIB;

D O I：

10.1016/j.clon.2010.04.008

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 [肿瘤学];

摘要：

The recent availability of molecular targeted therapies leads to reconsideration of the treatment strategy in patients with distant metastases from differentiated thyroid carcinoma who are resistant to radioiodine therapy, and in patients with metastatic medullary thyroid carcinoma. In patients with progressive disease, treatment with kinase inhibitors should be offered, preferably in the context of a prospective trial. (C) 2010 The Royal College of Radiologists. Published by Elsevier Ltd. All rights reserved.

引用

页码：448 / 455

页数：8

共 65 条

[1]

Treatment of anaplastic thyroid carcinoma with paclitaxel: Phase 2 trial using ninety-six-hour infusion [J].

Ain, KB ;

Egorin, MJ ;

DeSimone, PA .

THYROID, 2000, 10 (07) :587-594

[2]

The RET kinase inhibitor NVP-AST487 blocks growth and calcitonin gene expression through distinct mechanisms in medullary thyroid cancer cells [J].

Akeno-Stuart, Nagako ;

Croyle, Michelle ;

Knauf, Jeffrey A. ;

Malaguarnera, Roberta ;

Vitagliano, Donata ;

Santoro, Massimo ;

Stephan, Christine ;

Grosios, Konstantina ;

Wartmann, Markus ;

Cozens, Robert ;

Caravatti, Giorgio ;

Fabbro, Doriano ;

Lane, Heidi A. ;

Fagin, James A. .

CANCER RESEARCH, 2007, 67 (14) :6956-6964

[3]

[Anonymous], J CLIN ONCOL S

[4]

Prognostic impact of serum calcitonin and carcinoembryonic antigen doubling-times in patients with medullary thyroid carcinoma [J].

Barbet, J ;

Campion, L ;

Kraeber-Bodéré, F ;

Chatal, JF .

JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2005, 90 (11) :6077-6084

[5]

New therapeutic approaches for metastatic thyroid carcinoma [J].

Baudin, Eric ;

Schlumberger, Martin .

LANCET ONCOLOGY, 2007, 8 (02) :148-156

[6]

Bible KC, 2009, J CLIN ONCOL, V27

[7]

Thyroid-hormone therapy and thyroid cancer: a reassessment [J].

Biondi, B ;

Filetti, S ;

Schlumberger, M .

NATURE CLINICAL PRACTICE ENDOCRINOLOGY & METABOLISM, 2005, 1 (01) :32-40

[8]

PTEN expression is reduced in a subset of sporadic thyroid carcinomas:: evidence that PTEN-growth suppressing activity in thyroid cancer cells is mediated by p27kip1 [J].

Bruni, P ;

Boccia, A ;

Baldassarre, G ;

Trapasso, F ;

Santoro, M ;

Chiappetta, G ;

Fusco, A ;

Viglietto, G .

ONCOGENE, 2000, 19 (28) :3146-3155

[9]

Expression of angiogenesis stimulators and inhibitors in human thyroid tumors and correlation with clinical pathological features [J].

Bunone, G ;

Vigneri, P ;

Mariani, L ;

Butó, S ;

Collini, P ;

Pilotti, S ;

Pierotti, MA ;

Bongarzone, I .

AMERICAN JOURNAL OF PATHOLOGY, 1999, 155 (06) :1967-1976

[10]

Disease associated mutations at valine 804 in the RET receptor tyrosine kinase confer resistance to selective kinase inhibitors [J].

Carlomagno, F ;

Guida, T ;

Anaganti, S ;

Vecchio, G ;

Fusco, A ;

Ryan, AJ ;

Billaud, M ;

Santoro, M .

ONCOGENE, 2004, 23 (36) :6056-6063

← 1 2 3 4 5 6 7 →